Parkinson Hastalığında Tanı, Klinik ve Tedavi

Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474. PMID: 30584159; PMCID: PMC6311367.

Güler S, Caylan A, Turan N. Batı Türkiye’de İdiyopatik Parkinson Hastalığının Prevalansı ve Klinik Özellikleri. Arch Neuropsychiatry 2022;59:98−104.

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. PMID: 28332488.

Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23. PMID: 32576618.

Delenclos, M., Moussaud, S., & McLean, P. J. (2017). Lewy body dementia. In Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies (pp. 175-198). Elsevier. https://doi.org/10.1016/B978-0-12-805120-7.00008-7.

Oertel WH. Recent advances in treating Parkinson's disease. F1000Res. 2017 Mar 13;6:260. doi: 10.12688/f1000research.10100.1. PMID: 28357055; PMCID: PMC5357034.

Yang R, Gao G, Yang H. The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. Front Aging Neurosci. 2022 Jun 24;14:861035. doi: 10.3389/fnagi.2022.861035. PMID: 35813958; PMCID: PMC9263383.

Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010 Feb;16(2):79-84. doi: 10.1016/j.parkreldis.2009.08.007. Epub 2009 Oct 28. PMID: 19846332.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. PMID: 26474316.

Çakmur R, Günal Dİ (Ed). 2023. Hareket bozuklukları tanı ve tedavi rehberi. 2. Baskı. Türk Nöroloji Derneği. Ankara. 2023.

Elsworth JD. Parkinson's disease treatment: past, present, and future. J Neural Transm (Vienna). 2020 May;127(5):785-791. doi: 10.1007/s00702-020-02167-1. Epub 2020 Mar 14. PMID: 32172471; PMCID: PMC8330829.

Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul;73(4):682-9. PMID: 16878274.

Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA, 323(6), 548. doi:10.1001/jama.2019.22360.

Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000. PMID: 20932066.

Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, Jost WH. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. J Neural Transm (Vienna). 2023 Jun;130(6):847-861. doi: 10.1007/s00702-023-02623-8. Epub 2023 Mar 24. PMID: 36964457; PMCID: PMC10199833.

Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis. 2022;12(2):477-493. doi: 10.3233/JPD-212976. PMID: 34957948; PMCID: PMC8925102.

Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology. 2004 Jan;25(1-2):243-50. doi: 10.1016/S0161-813X(03)00103-7. PMID: 14697899.

Nawaz H, Sargent L, Quilon H, Cloud LJ, Testa CM, Snider JD, Lageman SK, Baron MS, Berman BD, Zimmerman K, Price ET, Mukhopadhyay ND, Barrett MJ. Anticholinergic Medication Burden in Parkinson's Disease Outpatients. J Parkinsons Dis. 2022;12(2):599-606. doi: 10.3233/JPD-212769. PMID: 34806617; PMCID: PMC9602053.

Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021 Dec;20(12):1048-1056. doi: 10.1016/S1474-4422(21)00249-0. Epub 2021 Oct 19. PMID: 34678171.

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Eur J Neurol. 2022 Sep;29(9):2580-2595. doi: 10.1111/ene.15386. Epub 2022 Jul 6. PMID: 35791766.

Malek N. Deep Brain Stimulation in Parkinson's Disease. Neurol India. 2019 Jul-Aug;67(4):968-978. doi: 10.4103/0028-3886.266268. PMID: 31512617.

Pessoa RR, Moro A, Munhoz RP, Teive HAG, Lees AJ. Apomorphine in the treatment of Parkinson's disease: a review. Arq Neuropsiquiatr. 2018 Dec;76(12):840-848. doi: 10.1590/0004-282X20180140. PMID: 30698208.

Nyholm D, Jost WH. Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. doi: 10.1177/17562864221108018. PMID: 35785401; PMCID: PMC9244918.